7,945 Shares in Bristol Myers Squibb Company $BMY Bought by Live Oak Investment Partners

Live Oak Investment Partners purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,945 shares of the biopharmaceutical company’s stock, valued at approximately $458,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. waypoint wealth counsel acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $34,406,000. Lazard Asset Management LLC boosted its holdings in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the period. Axxcess Wealth Management LLC grew its stake in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the last quarter. Finally, Asset One Wealth Management LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at about $4,075,000. Institutional investors own 76.41% of the company’s stock.

Get Bristol Myers Squibb alerts:

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $67.59 on Thursday. The business has a fifty day moving average price of $60.18 and a two-hundred day moving average price of $59.24. The stock has a market capitalization of $138.06 billion, a PE ratio of 14.89, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the business earned $1.46 earnings per share. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the topic of several research reports. Jefferies Financial Group downgraded Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lifted their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Royal Bank Of Canada increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Finally, TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Check Out Our Latest Research Report on Bristol Myers Squibb

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Featured Stories

• Five stocks we like better than Bristol Myers Squibb
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.